HomePink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo
Email Preferences
Free Trial
Email Preferences
Free Trial
Spotlight
  • China
  • Obesity
  • AI
  • Drug Pricing
  • Cell & Gene Therapies

Business
  • Deals
  • Financing
  • Earnings
  • Commercial Strategy
  • Approvals & Launches
  • Trial Results
  • Market Access
Disease
  • Cancer
  • Immune Disorders
  • Cardiovascular
  • Neurological
  • Rare Diseases

Deep Dives
  • Interviews
  • Data Insights
  • Scrip Asks
  • Disease Landscapes
Focus On Asia
  • Japan
  • South Korea
  • India
  • Scrip Asia 100

Tools & Trackers
  • Pipeline Watch
  • Finance Watch
  • Deal Watch
  • Stock Watch
  • Top Selling Drugs
  • Company Rankings
  • Executive Moves
Podcasts

Conference Coverage

Partner Insights

Scrip Perspectives

Previewing biopharma commercial, market access and development themes.

View

Pink Sheet

Scrip

Medtech Insight

HBW Insight

Generics Bulletin

In Vivo
Scrip logo
  1. Home
  2. >>Scrip
  3. >>Market Intelligence

Market Intelligence

Data InsightsTop Selling DrugsCompany Rankings
  • Scrip 100 Rankings Shake-Up: AstraZeneca, Lilly, Novo Nordisk And Amgen Climb Higher

    Scrip 100 Rankings Shake-Up: AstraZeneca, Lilly, Novo Nordisk And Amgen Climb Higher

    Jun 05 2026 
    • By Saba Afreen

    Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.

Norstella India logo
Twitter feedfooter-block.linkedin-linkRSS feedPodcastPodcast

About

  • About UsOpens in new window
  • Meet the Team
  • AdvertiseOpens in new window
  • Contact Us

Account

  • My Account
  • My View
  • Email Preferences
  • Start Free TrialOpens in new window

More

  • Scrip Perspectives
  • Scrip 100 Ranking
  • Scrip Asia 100
  • Conferences
  • Executives On The Move
  • Pipeline Watch
Home
Terms and ConditionsOpens in new window
Privacy PolicyOpens in new window